Updates on prevention, diagnosis, and treatment of GVHD and VOD/SOS

Abstract

Hematopoietic stem cell transplantation (HSCT) for pediatric and adult hematological diseases significantly differ regarding target diseases and complications. Although new technologies and drugs have emerged for prevention, diagnosis, and treatment in adults, caution is needed in applying these technologies to children. This study presents examples of pediatric hematological cancer treatments and provides recent information on the diagnosis and treatment of VOD/SOS, a severe post-HSCT complication. Moreover, it discusses updates on the prevention and treatment of GVHD by introducing new treatments, such as ibrutinib and ruxolitinib. Furthermore, long-term health management and follow-up of post-HSCT patients are crucial, with tools available to support these aspects.